Prenetics Global Ltd (PRE) FinancialsPREPrenetics Global Ltd

Prenetics Global Ltd (PRE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics , accounting for 91.3% of total sales, equivalent to $59.06M. Another important revenue stream is Prevention . Understanding this composition is critical for investors evaluating how PRE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Prenetics Global Ltd maintains a gross margin of 64.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -24.66%, while the net margin is -76.03%. These profitability ratios, combined with a Return on Equity (ROE) of -39.62%, provide a clear picture of how effectively PRE converts its operational activities into shareholder value.

In the context of the broader market, PRE competes directly with industry leaders such as KBON and FWDI. With a market capitalization of $441.96M, it holds a significant position in the sector. When comparing efficiency, PRE's gross margin of 64.76% stands against KBON's N/A and FWDI's 62.19%. Such benchmarking helps identify whether Prenetics Global Ltd is trading at a premium or discount relative to its financial performance.

Prenetics has demonstrated impressive revenue growth, with Q2 2026 revenue reaching $46.5 million, a 29% increase quarter-over-quarter and approximately 3.9 times year-over-year growth. The gross margin has been strong, averaging around 64.76% in Q1 2026, indicating effective cost management and product demand.